DB05636InvestigationalSmall molecule
(+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 (+)-Mefloquine Compared With Racemic Mefloquine) to compare the efficacy of (+)...
- Primary indication
- Investigated for use/treatment in rheumatoid arthritis.Curator reviewed
- Formula / weight
- C17H16F6N2O · 378.318 g/mol (avg)
- Also known as
- (+)-(11R,2'S)-erythro-mefloquine · [(11R,2'S)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol
- Code names
- AD-452
Resolves to
Structure
InChIKey
XEEQGYMUWCZPDN-SWLSCSKDSA-NSMILESO[C@@H]([C@@H]1CCCCN1)C1=CC(=NC2=C(C=CC=C12)C(F)(F)F)C(F)(F)FWhat you can answer from here — as of April 23, 2025
Which companies are running trials of (+)-Mefloquine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account